Wang Bin, Cai Ruyuan, Sun Tingting, Yang Zhufang, Zhang Hongjie
Department of Ophthalmology, Yancheng Third People's Hospital, Affiliated Hospital 6 of Nantong University, 75 Juchang Street, Yancheng, 224005, China.
Heliyon. 2024 Jul 6;10(13):e34243. doi: 10.1016/j.heliyon.2024.e34243. eCollection 2024 Jul 15.
With the rapid development of biotechnology, long non-coding RNAs (lncRNAs) have shown promising potential for cancer treatment and may become novel therapeutic targets. This study aimed to explore the roles of lncRNAs in retinoblastoma (RB). It involves analysing differentially expressed lncRNAs in RB and normal tissues from the GSE111168 and GSE125903 datasets, further validating them in RB cells. Our findings determined that lncRNA MIMT1 was upregulated in RB cell lines and tissues. In WERI-Rb1 and Y79 cells, silencing MIMT1 significantly inhibited cell proliferation, whereas MIMT1 overexpression enhanced cell proliferation. Furthermore, xenograft experiments demonstrated that MIMT1 knockdown suppressed tumour volume and weight. Subsequent mechanistic investigations showed that MIMT1 upregulates fibroblast expression of FGF2 by binding to miR-153-5p, ultimately promoting RB cell proliferation. This suggest that MIMT1 functions as an oncogene in RB and potentially serves as a molecular marker for diagnostic and prognostic assessments. Thus, the MIMT1/miR-153-5p/FGF2 pathway is a promising therapeutic target for RB treatment.
随着生物技术的快速发展,长链非编码RNA(lncRNAs)在癌症治疗方面显示出了广阔的潜力,并可能成为新的治疗靶点。本研究旨在探讨lncRNAs在视网膜母细胞瘤(RB)中的作用。它包括分析来自GSE111168和GSE125903数据集的RB组织和正常组织中差异表达的lncRNAs,并在RB细胞中进一步验证它们。我们的研究结果确定lncRNA MIMT1在RB细胞系和组织中上调。在WERI-Rb1和Y79细胞中,沉默MIMT1显著抑制细胞增殖,而MIMT1过表达增强细胞增殖。此外,异种移植实验表明,敲低MIMT1可抑制肿瘤体积和重量。随后的机制研究表明,MIMT1通过与miR-153-5p结合上调成纤维细胞中FGF2的表达,最终促进RB细胞增殖。这表明MIMT1在RB中作为癌基因发挥作用,并可能作为诊断和预后评估的分子标志物。因此,MIMT1/miR-153-5p/FGF2通路是RB治疗中一个有前景的治疗靶点。